What happens when an entire healthcare market has been built on evidence, systems, and investment assumptions that were never designed to see women properly?

That question has taken us from menopause and ADHD to diagnostic delay, fertility, chronic pain, longevity, healthcare financing, and the capital structures that determine which innovations ever reach women in the first place.

Over the last three years, this newsletter has grown into a global community of readers thinking seriously about women’s health, healthcare innovation, and the systems that determine what gets funded.

You have replied with your own stories. You have sent articles to friends, colleagues, doctors, founders, and investors. You have helped turn what began as a newsletter into a serious conversation about the future of women’s health.

I write because I love doing it but I also want to be transparent: each essay takes at least three to four hours to research, write, edit, and fact-check. The deeper pieces often take much longer. If this work is going to remain rigorous, independent, and increasingly useful, it needs a more sustainable foundation.

And I want to begin by giving those members something I have not published elsewhere—a bonus chapter “The Hidden Infrastructure Thesis” from my book, The Billion Dollar Blindspot.

Get the Founding Member Benefits

The Hidden Infrastructure Thesis

The bonus chapter of the book The Billion Dollar Blindspot asks a question most investors still miss:

What if the most valuable asset in a women’s-health company is not the product, but the infrastructure it has had to build because no one built it before?

The chapter follows the real-life stories of three founders confronting three different absences:

• A hormone-health company discovering that the data required to personalise treatment simply did not exist and deciding to build the dataset itself.

• A fertility-monitoring company spending fifteen years building something harder to measure but equally valuable: proof that the market is real.

• A cervical-cancer diagnostics company learning, through a supplier crisis, that quality systems and regulatory discipline are not administrative overhead. They are what allow a medical company to survive contact with the real world.

This chapter flips the investor lens. Instead of asking only, “Does the product work?” it asks:

• What infrastructure has this company built alongside the product?

• What would it take a competitor years to replicate?

• Which datasets, regulatory systems, clinical partnerships, quality frameworks, and market proof are becoming the real source of defensibility?

That distinction matters. Because in women’s health, founders are often not simply building businesses inside an established market. They are building the data foundations, regulatory pathways, operational systems, and legitimacy that other healthcare categories inherited from decades of prior investment. For the investor who can see that infrastructure early, the signal set changes.

Join as a founding member for $120 per year locked in for the first 250 members.

Get the Founding Member Benefits

Until next time,

Disclaimer & Disclosure

This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.

It aimed to treat the human body. But for much of its history, the body it studied first and treated as the reference point was male.

That did not always mean women were absent from research. The deeper problem was that female biology was often treated as a variable to be excluded or controlled for, rather than a source of information to be understood.

As a result, treatments were developed with an incomplete picture of how sex and life stage might alter response. Symptoms that presented differently in women were missed and conditions that evolved differently across a woman’s life were diagnosed late.

The consequences run through the full arc of a woman’s life: from hormonal health to cardiovascular disease, autoimmune disease, brain health, bone health, mental health, cancer, chronic pain, and ageing.

But a new paradigm is emerging. It is being driven by the convergence of scientific progress, new diagnostic and data capabilities, ageing populations, and the rising cost of treating disease too late.

Its consequences will reach far beyond medicine. They will reshape how healthcare is designed, how risk is understood, and where capital looks for the next generation of growth.

Share The Billion Dollar Blindspot

The old model of healthcare was built for a world of scarcity. Scarcity of data, diagnostic tools, computing power and longitudinal information about what happened to a person between one appointment and the next.

The practical response was to build systems around averages: standard pathways, broad populations, late intervention, and treatment after disease had already declared itself.

But that model is beginning to change. Genomics, biomarkers, more sensitive diagnostics, AI-enabled pattern recognition, wearables, remote monitoring, and new care-delivery models are making it possible to see disease earlier and with greater specificity. The ambition is no longer simply to treat a condition once it becomes obvious. It is to understand risk, monitor change, detect deviation, and intervene before a health problem becomes expensive, disabling, or irreversible.

This is what we mean by precision health—healthcare designed around the biological differences that determine who gets sick, how disease presents, what prevention looks like, and which treatment is most likely to work. Women’s health is one of the clearest tests of whether that transition is real.

Female biology affects disease risk, symptom presentation, progression, and treatment response across the life course.

Hormonal transitions can alter cardiovascular risk, bone density, cognition, metabolism, immune function, sleep, and mental health.

Pregnancy can reveal future cardiometabolic risk. Autoimmune disease disproportionately affects women. Chronic pain is more prevalent in women, yet has often been poorly understood and inadequately treated.

The National Institutes of Health now explicitly treats sex as a biological variable that should be considered in study design, analysis, and reporting. But policy recognition is not the same thing as full scientific integration. A recent National Academies review concluded that sex differences remain inconsistently implemented across research design and practice.

That gap is where the opportunity begins. When biology becomes more legible, markets once treated as peripheral become visible as infrastructure problems waiting to be solved.

A New Class of LPs is Forming

The capital signal is already visible. Over the past several years, private capital has begun to look at women’s health differently. The conversation has moved beyond whether the category is “investable” at all.

Increasingly, the questions are about access: which managers have real specialist expertise, where the strongest science is emerging, how to assess clinical and commercial maturity, and how to build exposure without reducing a global healthcare transition to one narrow theme. That shift is producing a new class of healthcare LPs.

It includes family offices looking for differentiated long-duration healthcare exposure; wealth managers responding to client interest in prevention, longevity, and healthcare innovation; entrepreneurial families with operating experience; healthcare executives; foundations; catalytic-capital providers; and next-generation capital stewards who see health not simply as a social issue, but as a structural economic one.

The Great Wealth Transfer which is currently ongoing through to the year 2048 matters here too. While the transfer of wealth to women does not mean that women who inherit or create wealth will automatically allocate to women’s health as capital decisions still remain shaped by mandate, risk appetite, family context, governance, and access.

But it does increase the number of people who hold, influence, or advise capital while also having direct experience of fertility care, pregnancy, chronic pain, menopause, caregiving, diagnostic delay, or the fragmented reality of healthcare systems.

This changes what they notice. It changes what they ask. It changes which questions reach private banks, family offices, investment committees, and advisers.

Investable before Institutionalisation

By now, the commercial case for women’s health is becoming harder to ignore.

There is growing scientific understanding. New companies are being built across diagnostics, therapeutics, care delivery, devices, data, and longevity. Private capital has begun to move into the category. And the underlying demand is not speculative: women are living longer, managing more chronic disease, and spending more years navigating healthcare systems that were not designed around their biology.

But recognition is not the same as access. A family office may see the opportunity and still struggle to answer a practical question: where, exactly, should we put capital to work?

That is because the category has developed faster than the infrastructure through which large pools of capital typically invest.

Institutional allocators typically invest through structures they can assess and govern: managers with long track records; vehicles that can absorb meaningfully sized tickets; benchmarks; portfolio-construction logic; and comparable data so that the opportunity can be evaluated alongside other healthcare allocations.

In women’s health, those structures are still emerging. This is not a reason to dismiss the category. It is a description of where the category sits in its development.

Climate investing offers a useful, limited parallel. The climate thesis was recognised before specialist managers, reporting standards, benchmarks, policy frameworks, and institutional familiarity had matured sufficiently for broad allocation. The thesis came first. The infrastructure followed. Capital scaled once it had credible routes through which to participate.

Women’s health is on a similar journey of capital formation, though not an identical one.

What the Biology Actually Does

The opportunity in women’s health is global, fragmented, and cross-disciplinary. It does not sit neatly inside one clinical category, one geography, one company type, or one investment stage. It stretches from diagnostics and therapeutics to care delivery, medical devices, data, ageing, and adjacent health technologies.

The expertise required to understand it is similarly dispersed. It often sits with specialist managers who have built relationships with founders, clinicians, researchers, hospitals, regulators, and local healthcare systems. These managers have developed the pattern recognition to identify a meaningful platform; the clinical networks to understand whether a therapy is genuinely differentiated; or the local knowledge to see where a care model can move from a promising service into durable infrastructure.

The strongest expertise is often held by these specialist managers that are relatively young in terms of track record, geographically dispersed, capacity constrained or too small for large institutional tickets. For larger allocators, that creates an access problem.

In this case, the answer is not simply to put more money into women’s health. The answer is to organise capital around specialist expertise: through disciplined manager selection, diversification across geography, clinical category, stage, and business model, governance, and institutional-quality portfolio construction.

The Question Capital Now Faces

Healthcare is becoming more precise. Private capital is beginning to seek exposure. The ownership and influence of wealth are changing. Yet the institutional architecture remains unfinished.

Women’s health is not a niche investment theme. It is where the transition to precision healthcare, the emergence of new healthcare LP demand, and the unfinished architecture of institutional capital meet.

The question is not whether this market will become more visible. It already is. The question is how we build credible routes for capital into the women’s health market.

The Women’s Health Capital Thesis Map

1. Part I: The Women’s Health Capital Thesis — You are here

2. Part II: Why Women’s Health Is the First Test of Precision Health — Coming next

3. Part III: The Emerging Healthcare LP: Why Private Capital Is Looking at Women’s Health Differently — Coming soon

4. Part IV: The Great Wealth Transfer Is an Accelerator, Not the Thesis — Coming soon

5. Part V: Investable Before Institutionalised — Coming soon

6. Part VI: Why Specialist Expertise Is the Missing Infrastructure — Coming soon

7. Part VII: Who Funds the Future of Healthcare? — Coming soon

These questions sit at the heart of my new book, The Billion Dollar Blindspot. The book explores how outdated assumptions shaped research, innovation, and investment in women’s health and why some of the most important opportunities in healthcare may emerge when those assumptions begin to break down.

I’m grateful that the book recently reached #1 New Release on Amazon in its category, a sign that more readers are beginning to engage with these ideas. Because this conversation is ultimately about much more than menopause, hormones, or even women’s health.

It is about what happens when we finally start looking at the world as it is, rather than as it used to be. If you’d like to explore these ideas more deeply, you can find The Billion Dollar Blind Spot on Amazon.

Order Your Copy

References

1. National Academies of Sciences, Engineering, and Medicine, Review of NIH Structure, Policies, and Programs for Women’s Health Research (2025); NIH Office of Research on Women’s Health, NIH-Wide Strategic Plan for Research on the Health of Women 2024–2028.

Disclaimer & Disclosure

This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.

Get Your Community Bonuses

You are twenty-eight weeks pregnant when the email arrives. It comes at an unremarkable moment: between meetings, in a supermarket queue, or while you are waiting for the kettle to boil. The subject line is easy to miss.

Important update about your health plan.

Inside, there is a sentence that changes the shape of your pregnancy. Your OB/GYN is longer be covered by your insurance. Not because you moved, or because your doctor retired, or because anything about your pregnancy changed. But because two large organisations are negotiating a contract.

Suddenly, the doctor who knows the miscarriage you do not like to speak about, the scan that frightened you, the question you asked only after your partner had left the room, may no longer be available to you, unless you can afford to pay far more to stay.

For the insurer, it is a network negotiation. For the provider group, it is a reimbursement dispute. But for the woman reading the email, it is the prospect of beginning again with someone new, halfway through the most consequential medical event of her life.

That is not a consumer inconvenience. It is a rupture in care.

A recent dispute involving Capital Women’s Care, a large US OB/GYN network affiliated with Unified Women’s Healthcare, made that rupture visible. During negotiations with UnitedHealthcare, patients were informed that their clinicians could fall out of network. For women already under their care, the practical choice appeared brutal: find another doctor mid-pregnancy or face potentially significant out-of-pocket costs to remain with the clinical team they trusted.

The dispute was ultimately resolved but it revealed a question far larger than one contract, one insurer, or one provider group:

What happens when the infrastructure of care becomes bargaining power?

Share The Billion Dollar Blindspot

Why Scale Enters The Room

To understand why women’s health practices are consolidating, it is important to begin with the pressures facing the practices themselves. The image of the independent doctor’s office is reassuring: a local clinic, a familiar receptionist, a physician who owns her practice and answers to her patients. But independence has become increasingly difficult to sustain.

Behind the consultation room is an expanding machinery of administration: insurance claims, coding, compliance, payroll, cybersecurity, electronic records, staffing shortages, regulatory reporting, and the constant negotiation of reimbursement rates. A small practice may be clinically excellent and still lack the capital, systems, or bargaining capacity required to survive in a healthcare economy built for scale.

For an OB/GYN practice, the demands can be even broader. Care does not stop at the consultation. It may involve ultrasound, laboratory services, hospital coordination, fertility referrals, maternal-fetal medicine, mental-health support, menopause care, and increasingly, digital tools that allow women to access care outside the narrow hours of a traditional clinic. Each layer requires people, technology, working capital, and time.

This is why larger platforms have become attractive to many clinicians. They can centralise billing and administration. They can recruit staff across a wider network. They can invest in electronic systems that a single practice could not justify alone. They can build integrated pathways across fertility, pregnancy, postpartum care, gynaecology, and menopause rather than leaving women to assemble their own care from disconnected providers.

That is the promise of scale. And it is a promise worth taking seriously. But scale is not neutral. Its consequences depend on the incentives behind it.

The Architecture Behind The Platform

This is where the conversation about private capital in healthcare usually collapses into caricature. Either private equity is cast as the villain: a financial machine that sees a clinic only as a line item to be optimised. Or it is cast as the saviour: the only source of capital and operational expertise capable of modernising a fragmented system.

Both stories are too easy. Capital is not a single force. It arrives with a design. It has a cost. A time horizon. A return expectation. A governance structure. It may carry debt. It may require an exit by a particular date. It may reward revenue growth, margin expansion, acquisition pace, or clinical outcomes. It may give doctors meaningful authority over care decisions or reduce them to employees inside a system whose priorities are set elsewhere. Those choices are not technical details buried in transaction documents. They are the architecture of the platform.

A care group can use capital to strengthen the clinical enterprise: to hire more physicians, invest in diagnostics, reduce administrative burden, modernise systems, and give clinicians the resources to spend more time doing the work only they can do. Or it can use capital to assemble assets rapidly, load the business with obligations, and make financial engineering the central source of value creation.

From the outside, both may present the same language: innovation, efficiency, access, growth. Both may have sleek websites. Both may announce new locations. Both may describe themselves as patient-centred. But the language of a platform does not tell us what its incentives are.

Its ownership architecture does. The relevant question, then, is not whether a women’s-health platform has private capital behind it. It is what that capital requires the platform to become. That distinction matters in every corner of healthcare. It becomes especially visible when the patient cannot simply choose another provider.

The Patient Cannot Step Out of the Negotiation

Most commercial relationships contain an exit. If a bank changes its terms, you can move your account. If a mobile provider raises its prices, you can change your contract. If a supermarket stops stocking what you buy, you go elsewhere.

The inconvenience may be real. But time is usually on your side. Healthcare does not work like that. And pregnancy makes the difference impossible to ignore.

A pregnancy has its own timetable. The next appointment is not optional because a contract is unresolved. A scan cannot be deferred until a new clinic has capacity. A woman managing gestational diabetes, pre-eclampsia risk, a complicated fertility history, or the memory of a previous loss cannot simply wait for the market to settle itself.

Nor is a clinician interchangeable. Medical records can be transferred. A chart can list blood pressure readings, test results, medication, and dates. But it cannot fully carry the accumulated knowledge of a relationship: what a patient has been afraid to say, which symptoms were dismissed elsewhere, how much reassurance she needs before a procedure, or the precise moment a clinician knows that something is wrong.

This is why the language of “choice” can be misleading in maternity care. Choice assumes comparable alternatives, available at the right time, within reach, covered by insurance, and able to take responsibility for a patient immediately. Often, those conditions do not exist.

The imbalance is not that one side has acted maliciously. Provider groups need reimbursement that allows them to retain clinicians and deliver care. Insurers have a responsibility to contain costs for their members. The imbalance is more basic. The institutions can negotiate. The patient cannot suspend the need.

And when a system treats continuity as a negotiable variable, the risk does not remain with the parties at the table. It moves through the system until it reaches the person with the least power to absorb it.

The Question Capital Must Answer

For years, the women’s-health conversation has rightly focused on what is missing. The diagnostic tests that do not exist. The conditions diagnosed too late. The therapies never developed. The research questions that were never asked because female biology was treated as a complication rather than a starting point. Those gaps remain enormous. But as capital begins to move into the category, another question becomes unavoidable:

What kind of infrastructure is that capital building?

Not simply:

• how many clinics were acquired?

• Or how quickly did revenue grow?

• Or how many patients entered the platform?

But:

• who owns the relationship between a woman and her care?

• What protects clinical judgement when commercial priorities tighten?

• What happens to continuity when a contract fails, a strategy changes, or a platform is sold?

• And which outcomes are important enough to sit beside margin, growth, and return on invested capital?

These are not peripheral questions for a mature women’s-health market. They are the questions that determine whether a category becomes more capable or merely more financialised.

The answer begins upstream. A capital allocator chooses a manager. A manager chooses a strategy. A strategy chooses an ownership model. And an ownership model decides, often quietly, which trade-offs become acceptable when growth, reimbursement, staffing, and patient care pull in different directions.

That is why capital allocation is never only about what gets funded. It is also about what gets normalised. Women’s health needs investment: in science, in clinicians, in care delivery, in technology, and in the systems that allow women to receive support across the full arc of their lives. But it needs capital with a longer view of value. Capital that understands that continuity is not a soft metric. That clinical autonomy is not a branding claim. That access is not merely a route to revenue. And that a care platform should be judged not only by what it can consolidate, but by what it can hold together.

Because when care becomes leverage, the cost of getting the architecture wrong is not borne by the people negotiating the contract. It is borne by the patient waiting for the phone to ring.

ADHD Series : The Part 3 of an investigative series examining ADHD in women, late diagnosis, perimenopause, hormonal influences on cognition, diagnostic bias, women's brain health, and related healthcare innovation and investment opportunities continues next week.

That question sits at the heart of my new book, The Billion Dollar Blindspot. The book explores how outdated assumptions shaped research, innovation, and investment in women’s health and why some of the most important opportunities in healthcare may emerge when those assumptions begin to break down.

I’m grateful that the book recently reached #1 New Release on Amazon in its category, a sign that more readers are beginning to engage with these ideas. Because this conversation is ultimately about much more than menopause, hormones, or even women’s health.

It is about what happens when we finally start looking at the world as it is, rather than as it used to be. If you’d like to explore these ideas more deeply, you can find The Billion Dollar Blind Spot on Amazon.

Order Your Copy

Disclaimer & Disclosure

This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.

Get Your Community Bonuses

She was 56 years old when she was finally diagnosed with ADHD.

The diagnosis arrived the way late diagnoses often do. Not as a revelation but as a reckoning. Decades of compensating. Decades of systems: the lists, the alarms, the overpreparation, the private terror of forgetting something important. Decades of believing, in the way women who have never been told otherwise tend to believe, that the effort required to function was a character flaw rather than a neurological one.

The diagnosis changed that. It gave the thing a name and then came the prescription. The drug was Vyvanse—lisdexamfetamine, sold in the UK and Europe as Elvanse, the same molecule under a different name. Her doctor was attentive. The dose was standard. She filled the prescription and took the first tablet the way you take anything you have been waiting for without knowing you were waiting for it.

What happened next, she did not expect. The medication made her sleepy. Not mildly tired, but deeply, dangerously sleepy. Then one afternoon, driving home from a weekend away with friends, she fell asleep at the wheel. It was noon. She woke as she crossed the double yellow line on a two-lane highway, her car moving directly towards a truck. The truck swerved. She swerved. They were both, as she later described it, very lucky.

When she told her doctor what had happened, he said something that has stayed with her ever since:

“That side effect is an indicator you have classic ADHD.”

She had not thought to ask (and no one had told her to ask) whether the medication had been specifically studied for how it behaves in women. whether the evidence behind her prescription had asked what happens when this drug meets a hormonal environment that changes every month or whether anyone, at any point in the drug’s development, had designed a study around that question.

A few weeks ago, another reader left a comment that stopped me mid-scroll:

“Please look into Elvanse and how different sexes respond.”

That comment received eleven likes because beneath it sits a much larger question:

The story of women and ADHD is usually told as a story of recognition. Women were missed. Women masked. Women compensated. Women were finally diagnosed.

That story is true but it stops one chapter too early.

Share The Billion Dollar Blindspot

Lisdexamfetamine did not arrive yesterday.

Vyvanse was introduced in the United States in July 2007 for children aged six to twelve and approved by the FDA for adults in April 2008. In the UK, NICE guidance offers lisdexamfetamine alongside methylphenidate as a first-line pharmacological option for adults with ADHD. When adult women now arrive at diagnosis — in their thirties, forties, fifties — the treatment pathway is already there. The drug, the dosing range, the prescribing guidance, and the clinical habits all exist.

This is the strange asymmetry of the moment. Women spent decades outside the diagnostic frame, and when the frame finally widened, they entered a treatment system that had already been built, already calibrated, and already closed.

The assumption, often unspoken, is that once the diagnosis is correct, the treatment question is mostly technical. Start low. Titrate. Monitor response. Adjust. But this assumes that the evidence base has already asked the questions that matter for the patient now sitting across from the clinician. In the case of women with ADHD, that assumption deserves scrutiny.

The Questions The Trials Did Not Ask

Read more

Get Your Community Bonuses

Imagine spending forty years believing something is wrong with you. Not seriously wrong but just enough wrong that you notice it.

You buy the planner. Then another. You create elaborate systems to stay organised. You write lists, set reminders, colour-code calendars, and leave yourself notes around the house. You arrive early because you’re afraid of being late. You overprepare because you’re afraid of forgetting. And you work twice as hard as everyone else to keep all the plates spinning.

From the outside, people think you have it together but inside, you are exhausted. You wonder why ordinary life seems to require so much more effort for you than it does for everyone else. Then one day — often in your forties or fifties — someone asks a question that stops you in your tracks.

Have you ever been assessed for ADHD?

Share The Billion Dollar Blindspot

At first, the suggestion seems absurd. ADHD is what little boys have. Not women with careers. Not mothers. Not executives. And certainly not the person who spent decades holding everything together through sheer force of will.

And yet, increasingly, that is exactly what is happening.

Women in their thirties, forties, and fifties are being diagnosed with ADHD in record numbers. For many, the diagnosis arrives with an unexpected mixture of emotions: relief, because finally there is an explanation; grief, because no one noticed sooner; anger, because years spent blaming yourself can never be returned. Running through almost every one of these stories is the same phrase in different forms.

But what if it wasn’t?

A few weeks ago, I wrote about Ambien, a sleep medication prescribed to women for nearly two decades at doses calibrated almost entirely on male data. It took regulators the better part of twenty years to acknowledge that women metabolised the drug differently. The lesson was not that researchers were malicious. It was that assumptions, once embedded in systems, become invisible. And once invisible, they stop being questioned.

The more I read about ADHD, the more that pattern began to feel familiar. For decades, the public face of ADHD was a young boy who couldn’t sit still; disrupting class, forgetting homework, bouncing off the walls. He was the child teachers noticed. The child parents worried about. The child researchers studied.

But what about the girls? The ones who daydreamed quietly, compensated, internalised and learned to hide their struggles instead of acting them out. If the condition was defined around the children who were easiest to notice, what happened to everyone else?

The question most coverage asks is: why are so many women being diagnosed now? The answer offered is usually awareness. Social media. Reduced stigma. Better clinician training. Those explanations may be true, but the more stories I encountered, the less convinced I became that this was the whole story.

Many women who receive late diagnoses describe not a gradual increase in awareness but a sudden collapse. A point in their forties when the systems that had held everything together for twenty years seemed to fail all at once. The lists stopped working. The calendar couldn’t keep pace. The effort required to function began exceeding what was available.

For a significant number of women, that moment appears to coincide with perimenopause. That coincidence is not random, and it is not well understood.

But it points toward something the awareness narrative misses entirely: that for many women, the real question is not why they are being diagnosed now.

The real question is what changed in their biology that made the invisible finally visible. Perhaps the real story is not that women are suddenly developing ADHD. Perhaps the real story is that they were always there and we never learned how to see them.

Over the coming weeks, I’m going to follow that question wherever it leads.

• Into the history of ADHD and how it became known as a boys’ disorder.

• Into the experiences of women who spent decades undiagnosed.

• Into the emerging science of hormones, cognition, and midlife brain health.

• And eventually, into the capital markets themselves.

Because if millions of women have been invisible to a diagnostic system for forty years, the implications extend far beyond medicine. They touch research priorities, innovation, healthcare delivery and investment.

Most of all, they force us to confront a possibility that sits at the heart of every blind spot. Sometimes what appears absent was there all along.

The first piece drops next week. If you have a personal experience with ADHD (medication, diagnosis or treatment), I’d love to hear from you.

Series Overview: This article is Part 1 of an investigative series examining ADHD in women, late diagnosis, perimenopause, hormonal influences on cognition, diagnostic bias, women's brain health, and related healthcare innovation and investment opportunities.

That question sits at the heart of my new book, The Billion Dollar Blindspot. The book explores how outdated assumptions shaped research, innovation, and investment in women’s health and why some of the most important opportunities in healthcare may emerge when those assumptions begin to break down.

I’m grateful that the book recently reached #1 New Release on Amazon in its category, a sign that more readers are beginning to engage with these ideas. Because this conversation is ultimately about much more than menopause, hormones, or even women’s health.

It is about what happens when we finally start looking at the world as it is, rather than as it used to be. If you’d like to explore these ideas more deeply, you can find The Billion Dollar Blind Spot on Amazon.

Order Your Copy

Disclaimer & Disclosure

This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.

Get Your Community Bonuses

On a summer morning in July 2002, phones began ringing in doctors’ offices across America. Women who had taken hormone therapy for years wanted answers. Should they stop? Had they put themselves at risk? Was the treatment they had trusted suddenly dangerous?

The questions were triggered by findings from the Women’s Health Initiative (WHI), one of the largest studies ever conducted on women’s health.

By evening, television news anchors were warning viewers about hormones. Within weeks, prescriptions were being cancelled. Within months, one of the most common treatments prescribed to midlife women had become something to fear.

Share The Billion Dollar Blindspot

The message travelled quickly. Far more quickly than the nuance. What began as a complex scientific discussion about risks, benefits, age, timing, and patient selection was gradually compressed into a much simpler narrative:

Hormones are dangerous.

For many women, that became the only message they ever heard. More than two decades later, we are still living with the consequences. Yet the most important consequence may not be what happened to hormone prescriptions. It may be what the episode revealed about how we think about women’s health.

For much of modern medical history, estrogen was viewed primarily through the lens of reproduction. Its role seemed obvious. It regulated menstrual cycles, supported fertility, enabled pregnancy and prepared the body for childbirth. When reproductive capacity ended, the assumption was often that estrogen’s most important work was largely done.

Women’s health, consciously or unconsciously, became organized around reproduction. It was a reasonable assumption. The question is whether it told the whole story.

But biology has a habit of refusing to fit neatly into our categories. Over time, researchers began discovering that estrogen was doing far more than helping women conceive children. Estrogen receptors were found throughout the body—in the brain, blood vessels, bones, muscles and in the heart.

Then we learnt that it helped maintain bone density, influenced vascular health, interacted with the cardiovascular system, played a role in cognition and brain health, and affected muscle mass and metabolism.

The reproductive role of estrogen had always been visible. Now what scientists were beginning to discover was everything else.

---

A new study published this month offers another clue that this broader understanding may be correct1. Researchers analyzed health records from more than 3.7 million postmenopausal women in South Korea and followed them for approximately ten years. The scale alone is remarkable. Over the course of the study, more than 48,000 women were hospitalized for heart failure, giving researchers an unusually large dataset from which to examine patterns. What they found was striking.

One study does not settle a scientific debate. Nor should it. Science advances through accumulation, not headlines. But when viewed alongside a growing body of research, the findings point in a consistent direction.

The effects of estrogen appear to extend well beyond fertility. The hormone may be influencing systems that shape cardiovascular health, resilience, and long-term outcomes throughout a woman’s life.

For most of human history, this question would have mattered far less. Life expectancy was shorter. Many women simply did not live long enough to spend decades beyond menopause. The years after reproduction existed, but they occupied a much smaller portion of life.

That is no longer true. Today, women can expect to spend more than a third of their lives in the postmenopausal phase. Pause on that for a moment. Not a brief chapter between middle age and old age but decades.

For many women, the years after reproduction may last longer than the years before it—a span of life longer than many people once lived altogether. Yet much of modern medicine still reflects assumptions formed in a different era. An era when women simply did not spend thirty, forty, or fifty years beyond menopause.

The demographic reality is changing but the underlying model has not, and that mismatch is becoming harder to ignore. It is beginning to show up everywhere. In cardiovascular disease, osteoporosis, cognitive health, metabolic health, in frailty and mobility, and in the growing realization that longevity looks different in women than it does in men.

The question facing medicine is no longer simply how to support women’s reproductive health. It is now how to support women’s health across the decades that follow reproduction, and the distinction matters. Because once those decades move from the margins to the center of the conversation, entirely new questions begin to emerge—new research priorities, new therapeutic opportunities, new markets and perhaps most importantly, a new understanding of what women’s health actually means.

Whenever our understanding of a problem changes, opportunities emerge. Not because the world changes overnight, but because we begin to see parts of it that were previously hidden.

For decades, women’s health was largely viewed through the lens of reproduction. That framing shaped research agendas, clinical priorities, innovation, and inevitably, it shaped where capital flowed. The result was a healthcare ecosystem that became attuned to fertility, pregnancy, and childbirth while devoting comparatively less attention to the decades that followed.

Yet those decades are no longer a footnote. They are becoming one of the defining health challenges and opportunities of the 21st century. The implications extend far beyond menopause itself. They touch cardiovascular disease, bone health, cognitive decline, metabolic health, mobility and healthy aging.

In other words, some of the largest health challenges facing women later in life may be connected to the very biological systems we once viewed primarily through a reproductive lens.

That realization is beginning to change the conversation. Researchers are asking new questions. Founders are building new companies. Clinicians are revisiting old assumptions, and investors are starting to look more closely at categories that were once dismissed as niche.

What makes this moment particularly interesting is that the opportunity was not created by a scientific breakthrough alone nor by a new technology. It emerged because demographics changed while our assumptions remained the same. Women did not suddenly start aging differently. We simply reached a point where millions of women were spending thirty, forty, and even fifty years beyond reproduction, forcing us to confront questions that had been hiding in plain sight.

That question sits at the heart of my new book, The Billion Dollar Blindspot. The book explores how outdated assumptions shaped research, innovation, and investment in women’s health and why some of the most important opportunities in healthcare may emerge when those assumptions begin to break down.

I’m grateful that the book recently reached #1 New Release on Amazon in its category, a sign that more readers are beginning to engage with these ideas. Because this conversation is ultimately about much more than menopause, hormones, or even women’s health.

It is about what happens when we finally start looking at the world as it is, rather than as it used to be. If you’d like to explore these ideas more deeply, you can find The Billion Dollar Blind Spot on Amazon.

Order Your Copy

Disclaimer & Disclosure

This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.

A few years ago, a health diagnosis sent me into the healthcare system in a way I had never experienced before. The…

Read more

Get Your Community Bonuses Here

Read more

Pre-order here

Read more

Pre-order here

The acquisition is being covered as a story about the race to own “immune system reset” technology. That read is correct. But the most important commercial logic embedded in this deal has not appeared in any coverage published so far.

Subscribe now

What happened

On May 3, 2026, UCB, the Belgian biopharmaceutical company, announced an agreement to acquire Candid Therapeutics for $2 billion upfront, with up to $200 million in additional milestone payments. Total deal consideration: up to $2.2 billion. The transaction is expected to close by end of Q2 to early Q3 2026.

Candid Therapeutics is a US-based clinical-stage company developing a new class of autoimmune drugs. Its lead asset, cizutamig, works by directing the body’s own immune cells to identify and destroy the specific cells responsible for producing the antibodies that drive autoimmune disease and effectively clearing the source of the problem rather than suppressing the immune system broadly.

As of the acquisition announcement, more than 100 patients had received cizutamig, including 68 with autoimmune diseases. Global Phase 2 studies are planned in myasthenia gravis and interstitial lung disease. Earlier-stage evaluation is also underway across additional autoimmune indications including lupus, rheumatoid arthritis, systemic sclerosis-associated disease, and IgA nephropathy.

UCB describes the acquisition as part of a platform-driven strategy in next-generation immunology — a deliberate move to own multiple targeting approaches before the field matures.

Why it matters

The coverage this week is framing this as a story about platform immunology. Two billion dollars for a clinical-stage company with a novel mechanism, before pivotal proof. A high-conviction bet on the thesis that if you can eliminate the cells producing the antibodies that drive autoimmune disease, you may produce durable remission rather than managing symptoms indefinitely. That read is accurate. It is also incomplete.

The most important commercial logic embedded in this deal has not appeared in any coverage published this week. In this edition I will name it, explain why it changes how capital allocators should read the acquirer landscape in this space, and deliver six observations on where to be positioned before the next announcement; three on what the deal signals now, and three on what to track as the thesis develops.

Read more

Pre-order here

Read more

Pre-order here

Veozah launched in 2023 as the first non-hormonal oral treatment for menopause symptoms. Two and a half years later, the commercial revolution the category promised has not arrived. Bayer launched its competitor anyway. Here is what that tells capital allocators.

Subscribe now

What happened

In May 2023, Astellas’ Veozah became the first FDA-approved non-hormonal oral treatment for the hot flashes and night sweats affecting approximately 75% of women during the menopause transition. Astellas projected US revenues of $375 million in the drug’s first year of commercialisation.

In FY2024, its second full year on market, Veozah generated approximately $220 million globally. In December 2024, the FDA added a black box warning for rare but serious liver injury; the most prominent safety flag the agency can attach to a prescription drug.

Fast forward to October 2025 and Bayer’s Lynkuet received FDA approval for the same indication. It targets both the NK1 and NK3 receptors, a dual mechanism that Veozah does not carry. Importantly, it has no black box warning. Bayer made it commercially available in November 2025 and estimates annual peak sales of approximately €1 billion.

In April 2026, BioPharma Dive published a survey of persistent structural barriers in women's health drug development, noting that despite two approved non-hormonal drugs and a large unaddressed patient population, Veozah has faced slower-than-expected sales and reimbursement complications.

Why it matters

The coverage this week is framing this as a competitive story. Two drugs, same indication, different mechanisms. One with a cleaner safety profile. The question most coverage is asking is which company wins the menopause hot flash market.

That is the wrong question for capital allocators and in this piece, I will cover the one development most coverage has missed entirely, and share three observations on what this category dynamic tells capital allocators in women’s health about where to be positioned before the next announcement.

Read more

Pre-order here

Read more

Pre-order here

The largest overseas acquisition in Indian pharmaceutical history transferred the world's biggest dedicated women's health portfolio to a biosimilar manufacturer. Here is what that means for where the exits go from here.

Subscribe now

What happened

On 26 April 2026, Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion. The offer price of $14 per share represents a 24% premium to Organon’s closing price the previous Friday. The deal is the largest overseas acquisition in Indian pharmaceutical history.

The transaction transfers Organon’s full portfolio to Sun: Nexplanon, the world’s leading contraceptive implant; NuvaRing; Follistim for fertility; and a biosimilar portfolio including Hadlima and Renflexis. It also transfers Organon’s commercial infrastructure in China, where the company generates more than $800 million in annual revenue.

Combined, the two entities are projected to generate approximately $12.4 billion in revenue, placing the merged group among the 25 largest pharmaceutical companies globally.

Sun Pharma anticipates becoming a top-three global player in women’s health and the seventh-largest biosimilar company worldwide. The deal is expected to close in early 2027, pending regulatory approvals and shareholder consent.

Why it matters

Read more

In a recent episode of Blindspot Capital, I sat down with to explore what happens when a market begins not with products or funding but with missing information.

When Ann-Marie launched her newsletter in 2020, she wasn’t trying to build a company. She was trying to make sense of her own body. What she found instead was something far bigger: a fragmented, contradictory, and often commercialized information landscape where women were left to navigate perimenopause largely on their own. So she started writing.

What began as a weekly research letter has since grown into a global community spanning more than 20,000 women across 40 countries—an ecosystem built not on products, but on trust, nuance, and lived experience.

But this conversation is not about content creation. It’s about what has to exist before markets can function at all.

We talk about:

• Information as infrastructure: why women’s health markets are being built on community-led knowledge systems and what happens when reliable information doesn’t exist

• Trust vs. scale: why credibility in women’s health is earned through lived experience and nuance not reach, virality, or clinical authority alone

• The danger of certainty: how overly simplified narratives (especially around hormone therapy) can signal bias rather than truth

• The education burden on women: why midlife women are forced to become their own researchers, clinicians, and decision-makers in the absence of clear guidance

• Fear as a business model: who benefits when women are confused, overwhelmed, or anxious and how that shapes the entire category

🎧 Watch the full episode on YouTube

📄 Learn more about Hot Flash Inc. and share this episode

Pre-order here

Read more

Pre-order here

Gilead just paid $5 billion for a Munich biotech company. The deal was announced on Monday. The people who benefited from it were positioned years ago and in this article, I'm breaking down the signals they were watching so you know how to find the next one before the announcement.

Subscribe now

What happened

Gilead first partnered with Tubulis in December 2024 under an option and license agreement worth up to $465 million. Sixteen months later it didn’t just exercise the option. It bought the company.

What happened in between matters. Tubulis reported a 59% overall response rate in platinum-resistant ovarian cancer — an indication with no adequate standard of care and a patient population chronically underserved by both clinical investment and capital attention. The data moved Gilead from partner to acquirer.

And Gilead wasn’t the first major US strategic to take notice. BMS had also licensed Tubulis technology in 2023 for over $1 billion in milestones. Two of the world’s largest pharmaceutical companies had independently validated the same European platform.

Why it matters

US public R&D funding is under sustained structural pressure. Large pharma cannot rebuild deep-tech platform capability internally at the pace the competitive landscape demands. The efficient path (and Gilead has taken it three times this year alone) is acquisition of platform assets that have absorbed early-stage risk, demonstrated clinical signal, and retained scientific talent onshore. Tubulis is the European chapter of that strategy.

But here is the read that most coverage is missing this week.

When BMS licensed Tubulis technology in 2023, they validate the platform with that signal. When Gilead partnered sixteen months later, the auction had effectively started; it just hadn’t been announced yet.

That pattern — strategic partnership as a structured private option, clinical data as the conversion trigger, acquisition as the public confirmation — is not unique to Tubulis. It is how large pharma has been systematically acquiring European deep-tech biotech for the better part of a decade.

It just rarely happens at this scale, with this speed, and with a women’s health indication (ovarian cancer) anchoring the lead program.

That last fact is the one worth sitting with. The women’s health indication didn’t discount this exit. It justified it and that distinction is about to matter for every European platform asset currently sitting at Series B or C with a gynecologic oncology program in the lead position.

What this signals for investors

The most important thing about the Tubulis exit isn’t the size.

Read more

Pre-order here

Read more

Pre-order here

The most important acquirer in women’s health pharmaceuticals is subtly telling the market what it has become. Its not doing so through a press release but rather through a sequence of decisions made between October 2025 and March 2026 that, read together, paint a specific picture. Most investors in this space are reading them separately and that is the gap.

Organon, the MSD spin-out that holds Nexplanon, NuvaRing, and one of the largest women’s health commercial footprints in the world has spent the last five months selling assets, dropping R&D programs, licensing commercial-stage devices, running without a permanent CEO, and watching its share price sit roughly 63% below its three-year high. A non-binding acquisition approach from Sun Pharma surfaced in January, was publicly labelled speculative within days, and has since gone quiet.

What happened

Between October 2025 and March 2026, Organon:

• lost its founding CEO to a Nexplanon sales irregularity investigation

• reported full-year 2025 revenue of $6.2B against $8.64B in debt

• cut its quarterly dividend to $0.02

• discontinued its entire internal R&D pipeline for endometriosis and PCOS (both acquired via Forendo in 2021)

• divested its JADA postpartum hemorrhage system for $465M

• and licensed in MIUDELLA, the first new hormone-free copper IUD in the US in 40 years for $27.5M upfront.

In addition, guidance for FY 2026 is flat and the permanent CEO search is ongoing.

Why it matters

What Organon’s portfolio moves reveal is a deliberate strategic retreat: from originating science in women’s conditions toward distributing and commercialising proven products.

That is a rational response to $8.64B in debt and a governance crisis. It is also a structural shift in what Organon is and what it can offer the ecosystem that has been building toward it as an acquirer.

The endometriosis and PCOS pipeline drops are worth sitting with. These are two of the highest-unmet-need, highest-diagnostic-delay conditions in women’s health. Organon acquired rights to drug candidates in both, and has now walked away from both. At the same time, it licensed a commercial-stage contraceptive device.

That sequencing tells you something precise about what Organon is becoming. The more important question for anyone building or backing companies in this space is what that becoming means for where exits go from here.

Read more

In a recent episode of Blindspot Capital, I sat down with Lindsay Davis, founder of FemTech Association Asia, to talk about what it actually takes to build women’s health markets in Southeast Asia.

When Lindsay moved to Singapore in 2020, she wasn’t planning to work in women’s health. But what she noticed was difficult to ignore: founders, policymakers, and investors were all present, but disconnected. There was no shared infrastructure, no unified ecosystem, and no clear pathway for innovation to scale. So she started building.

What began as a simple act of connecting people has evolved into one of the largest specialist networks for women’s health innovation across Asia spanning research, partnerships, founder support, and ecosystem development.

But this conversation is not about startup growth. It’s about what has to exist before growth is even possible.

We talk about:

• Ecosystem building before capital: why markets don’t emerge fully formed and why infrastructure matters long before funding arrives

• The education burden on founders: how stigma and low awareness shape how companies are built in Asia

• Regional complexity: why Southeast Asia is not a single market, but a matrix of cultures, systems, and behaviors

• The visibility gap: how lack of data and precedent keeps women’s health overlooked by investors

• Capital flows in Asia: where femtech funding is actually coming from and how that is beginning to shift

What emerges from this conversation is a different understanding of women’s health.

🎧 Watch the full episode on YouTube

📄 Learn more about FemTech Association Asia and share this episode.